Arcellx, Inc.
ACLX
Rangering i aksjer
#2788
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Aksjekurs
$115.07
Sist synkronisert: 2026-05-15
Markedsverdi
$6.73B
Endring (1 dag)
0.00%
Endring (1 år)
34.40%
Land
US
Handel Arcellx, Inc. (ACLX)
Kategori
Healthcare
Inntekter for Arcellx, Inc. (ACLX)
Inntekter i Dec 2025 TTM: $22.29M
Ifølge de nyeste økonomiske rapportene til Arcellx, Inc. er selskapets nåværende inntekter (TTM) $22.29M. I 2023 hadde selskapet inntekter på $110.32M en økning sammenlignet med inntektene i 2022, som var 0.00. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Arcellx, Inc. fra 2018 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $22.29M | -79.35% |
| 2024 | $107.94M | -2.16% |
| 2023 | $110.32M | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | 56,546.77% |
US
|
|
| $2.23B | 9,897.31% |
US
|
|
| $15.74B | 70,546.72% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 26,918.25% |
NL
|
